President Trump fast tracks psychedelics for mental health, signing an executive order on Saturday, April 18, 2026, that dramatically accelerates the federal review and accessibility of psychedelic drugs for treating mental health disorders. This monumental move signals a profound departure from decades of stringent federal drug policy and could reshape the landscape of mental healthcare in America.
The executive order, signed in the Oval Office, saw President Trump flanked by Health and Human Services Secretary Robert F. Kennedy Jr., prominent podcaster Joe Rogan, and several military veterans. The administration frames this initiative as a direct and urgent response to the nation’s escalating mental health crisis, citing alarming statistics: over 14 million American adults grapple with a serious mental illness, with approximately 8 million currently relying on prescription medication. The current classification of substances like ibogaine, psilocybin, LSD, and MDMA as Schedule I drugs – deemed to have no accepted medical use and a high potential for abuse – has long been a barrier to research and therapeutic application. This executive action aims to dismantle those barriers.
Federal Investment and Expedited Review
A cornerstone of the President’s initiative is a significant federal investment of $50 million dedicated to psychedelic research. This funding will not only bolster federal efforts but also support state-level programs already advancing psychedelic drug research, with Texas notably having committed an additional $50 million specifically to ibogaine research. The executive order directly instructs the Food and Drug Administration (FDA) to prioritize the review of psychedelic compounds. In a groundbreaking announcement, FDA Commissioner Marty Makary revealed that three psychedelics would be added to the National Priority Voucher pilot program, a mechanism designed to drastically reduce review times from months to mere weeks. This marks an unprecedented level of fast-tracking for psychedelics by the FDA.
Furthermore, the FDA is set to initiate human trials for ibogaine, a substance with a complex history due to its known cardiovascular toxicity. The order also leverages the ‘Right To Try’ rule, a law signed by Trump during his first term, opening a vital pathway for “desperately ill patients” to access ibogaine. This provision could offer a lifeline to individuals for whom traditional treatments have failed.
President Trump also affirmed that any FDA-approved psychedelics would be promptly rescheduled, making them significantly easier to access for therapeutic use. The order specifically instructs the Attorney General to conduct these rescheduling reviews earlier, potentially shaving off up to three months of administrative delays. This proactive approach underscores the administration’s commitment to rapidly integrate these therapies into mainstream medicine once validated.
Focus on Veterans and Expert Reactions
A substantial emphasis of the executive order is placed on veterans, a demographic disproportionately affected by mental health challenges. The Department of Veterans Affairs (VA) is already actively participating in at least five trials of these drugs across New York, California, and Oregon. Health Secretary Robert F. Kennedy Jr. highlighted a critical concern: many veterans are currently traveling to other countries, such as Mexico, to access these treatments, underscoring the urgent need for domestic availability and regulated access.
“Federal prohibition of psychedelic medicine in America is over.”
The announcement has sparked a wave of reactions across various sectors. Advocates like W. Bryan Hubbard, a fervent ibogaine proponent, unequivocally declared, “Federal prohibition of psychedelic medicine in America is over.” Former Navy SEALs Marcus Luttrell and Robert O’Neill shared compelling personal testimonies, detailing how psychedelics have profoundly improved veterans’ mental health. Podcaster Joe Rogan, a long-time advocate for increased access to psychedelics, is credited with helping bring this issue to the President’s attention, illustrating the growing influence of public figures in shaping policy.
However, the move is not without its critics. Kevin Sabet, a former White House drug policy adviser, voiced concerns about potential unintended public health consequences, warning against “hasty, potentially dangerous research” and highlighting a perceived lack of robust evidence for many of these drugs. Frederick Barrett, director of the Johns Hopkins Center for Psychedelic and Consciousness Research, acknowledged the historical challenges in studying ibogaine due to its known “cardiovascular toxicity” – a factor linked to over 30 reported deaths in medical literature – but expressed hope that the order would facilitate objective scientific research.
Market Implications and Global Context
The market impact of this executive order is anticipated to be substantial, likely encouraging further private sector investment in psychedelic research and development. World-leading institutions such as Stanford, Harvard, and Johns Hopkins are already actively engaged in studying psychedelic therapies, and some psychedelic drugs have previously received “Breakthrough Therapy” designation from the FDA, signaling preliminary evidence of substantial improvement over existing treatments. This federal push to fast track psychedelics for mental health is poised to ignite a new wave of innovation and investment in the nascent psychedelic medicine industry. For more trending stories, visit our news section.
This executive order represents a dramatic pivot from the strict federal drug policy that has defined the United States for decades, largely shaped by the ‘war on drugs’ initiated by the Nixon administration. While substances like psilocybin, MDMA, and LSD remain illegal Schedule I substances, the administration’s actions are explicitly designed to ease these restrictions and vigorously spur research into their profound medical potential. This federal embrace of psychedelic inquiry follows a discernible trend at the state level, where trailblazers like Oregon and Colorado have already legalized psychedelic therapy with psilocybin. The implications are vast, suggesting a future where carefully regulated psychedelic-assisted therapies could become a mainstream option for millions battling mental health disorders, fundamentally altering the landscape of psychiatric treatment and drug policy for generations to come. The world will be watching closely as this bold experiment unfolds.
